Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 9 | 2024 | 1463 | 0.900 |
Why?
|
Neurotoxicity Syndromes | 2 | 2023 | 300 | 0.770 |
Why?
|
Leukapheresis | 2 | 2023 | 134 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2024 | 1404 | 0.640 |
Why?
|
Sepsis | 2 | 2023 | 2583 | 0.630 |
Why?
|
bcl-X Protein | 3 | 2024 | 410 | 0.550 |
Why?
|
Antigens, CD19 | 4 | 2024 | 425 | 0.540 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5663 | 0.520 |
Why?
|
Lymphotoxin beta Receptor | 2 | 2024 | 24 | 0.470 |
Why?
|
Sulfonamides | 1 | 2024 | 1973 | 0.470 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 1373 | 0.410 |
Why?
|
T-Lymphocytes | 6 | 2024 | 10188 | 0.380 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1549 | 0.370 |
Why?
|
Bile Duct Neoplasms | 3 | 2024 | 605 | 0.330 |
Why?
|
Apoptosis | 2 | 2024 | 9468 | 0.320 |
Why?
|
Lymphotoxin-beta | 2 | 2024 | 14 | 0.300 |
Why?
|
Transcription Factor RelB | 2 | 2024 | 28 | 0.300 |
Why?
|
Cholangiocarcinoma | 2 | 2024 | 552 | 0.300 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3590 | 0.260 |
Why?
|
Transplantation, Homologous | 3 | 2023 | 4808 | 0.250 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2531 | 0.240 |
Why?
|
B-Cell Maturation Antigen | 1 | 2024 | 149 | 0.210 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 468 | 0.210 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1890 | 0.200 |
Why?
|
Viral Matrix Proteins | 1 | 2022 | 196 | 0.180 |
Why?
|
Endopeptidases | 1 | 2024 | 772 | 0.180 |
Why?
|
Biliary Tract Neoplasms | 1 | 2022 | 184 | 0.180 |
Why?
|
Lymphocyte Count | 1 | 2020 | 778 | 0.150 |
Why?
|
Liver Neoplasms | 2 | 2023 | 4319 | 0.140 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 16945 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2022 | 831 | 0.120 |
Why?
|
Stem Cell Transplantation | 1 | 2023 | 1598 | 0.120 |
Why?
|
Remission Induction | 1 | 2020 | 2394 | 0.120 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3874 | 0.110 |
Why?
|
Flow Cytometry | 1 | 2024 | 5865 | 0.110 |
Why?
|
Neoplasms | 1 | 2022 | 22083 | 0.110 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 1640 | 0.110 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4509 | 0.100 |
Why?
|
Peptide Fragments | 1 | 2024 | 5105 | 0.100 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6894 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2024 | 10425 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2297 | 0.090 |
Why?
|
Humans | 21 | 2024 | 760437 | 0.090 |
Why?
|
Biological Products | 1 | 2020 | 911 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2319 | 0.090 |
Why?
|
Kidney Failure, Chronic | 1 | 2022 | 2462 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2021 | 3541 | 0.080 |
Why?
|
Recurrence | 1 | 2020 | 8466 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5359 | 0.070 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5143 | 0.060 |
Why?
|
Mice | 4 | 2024 | 81402 | 0.060 |
Why?
|
Signal Transduction | 2 | 2024 | 23397 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15820 | 0.050 |
Why?
|
Retrospective Studies | 2 | 2022 | 80430 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3027 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4586 | 0.050 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2022 | 83 | 0.050 |
Why?
|
Cytomegalovirus Vaccines | 1 | 2022 | 17 | 0.050 |
Why?
|
DNA Modification Methylases | 1 | 2022 | 210 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2022 | 296 | 0.050 |
Why?
|
DNA Repair Enzymes | 1 | 2022 | 346 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 326 | 0.040 |
Why?
|
Animals | 4 | 2024 | 168253 | 0.040 |
Why?
|
Cohort Studies | 1 | 2022 | 41366 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1021 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 15476 | 0.040 |
Why?
|
Prognosis | 3 | 2023 | 29551 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13616 | 0.040 |
Why?
|
Middle Aged | 5 | 2024 | 220382 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2022 | 755 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 59068 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2485 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9267 | 0.030 |
Why?
|
Adult | 4 | 2024 | 220781 | 0.030 |
Why?
|
Aged | 3 | 2024 | 168840 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2022 | 2018 | 0.030 |
Why?
|
Male | 5 | 2024 | 360035 | 0.030 |
Why?
|
Female | 5 | 2024 | 391875 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1725 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2895 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2803 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2622 | 0.020 |
Why?
|
Medical Oncology | 1 | 2020 | 2318 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2529 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10075 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3818 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4575 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2020 | 3457 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3596 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7849 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2022 | 4226 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6330 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39078 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10698 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 23953 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54339 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 58859 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2021 | 64591 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88196 | 0.010 |
Why?
|
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_